<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05070832</url>
  </required_header>
  <id_info>
    <org_study_id>PUTHRC-001</org_study_id>
    <nct_id>NCT05070832</nct_id>
  </id_info>
  <brief_title>Hyperthermia Combined With Neoadjuvant Radiochemotherapy for LARC</brief_title>
  <acronym>PUTHRC-001</acronym>
  <official_title>Deep Hyperthermia Combined With Neoadjuvant Concurrent Radiochemotherapy for Locally Advanced Rectal Cancer, PUTHRC-001：A Multi-Center, Open-Label, Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether adding deep hyperthermia to neoadjuvant&#xD;
      concurrent radiochemotherapy could improve T-downstaging rate for locally advanced rectal&#xD;
      cancer (LARC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether adding deep hyperthermia to neoadjuvant&#xD;
      concurrent radiochemotherapy could improve T-downstaging rate for locally advanced rectal&#xD;
      cancer (LARC). The sample size is 142. Patients with LARC (T3-4/N+) will be randomly divided&#xD;
      into intervention group and control group. For intervention group, the neoadjuvant therapy is&#xD;
      hyperthermia combined with concurrent radiochemotherapy. For control group, the neoadjuvant&#xD;
      treatment is concurrent radiochemotherapy. T-downstaging rate will be used to evaluate the&#xD;
      effectiveness of deep hyperthermia. T-downstaging is defined as the postoperative&#xD;
      pathological T stage lower than the original T stage by imaging before treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor T-downstaging rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>T-downstaging is defined as the postoperative pathological T stage lower than the original T stage by imaging before treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor shrinkage percentage</measure>
    <time_frame>12 weeks</time_frame>
    <description>（tumor volume before treatment-tumor volume before neoadjuvant treatment) /（ tumor volume before neoadjuvant treatment）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete tumor resection rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>（patient number of R0 resection）/（total number of patients undergoing surgery）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>（number of patients with no residual tumors after neoadjuvant therapy）/（total number of patients undergoing surgery）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative complication rate</measure>
    <time_frame>4 months</time_frame>
    <description>（number of patients with complications before or after surgery）/（total number of patients undergoing surgery）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anal retention rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>（number of patients with anus preservation after surgery）/（total number of patients undergoing surgery）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3 year</time_frame>
    <description>the time from random day to disease progression or death (whichever occurs first);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 year</time_frame>
    <description>the time between a random day and the day of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>36-Item Short-Form Health Survey（SF-36）</measure>
    <time_frame>3 year</time_frame>
    <description>The minimum and maximum values of SF-36 are 30 and 150. Higher score means a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire-Core 30（QLQ-C30）</measure>
    <time_frame>3year</time_frame>
    <description>The minimum and maximum values of QLQ-C30 are 0 and 100. Higher score means a better quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Hyperthermia</condition>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Hyperthermia Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The neoadjuvant therapy is hyperthermia combined with concurrent radiochemotherapy for this group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-hyperthermia group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The neoadjuvant treatment is concurrent radiochemotherapy, which is standard treatment for LARC according to the guidelines.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Deep Hyperthermia</intervention_name>
    <description>Hyperthermia is a type of treatment in which tumor is heated to as high as 40.5-43℃ to help damage and kill cancer cells with little or no harm to normal tissue.</description>
    <arm_group_label>Hyperthermia Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years old&#xD;
&#xD;
          -  Pathologically diagnosed as rectal adenocarcinoma&#xD;
&#xD;
          -  Locally advanced rectal cancer (T3-4/N+) staging by CT, MRI and/or endoscopy&#xD;
&#xD;
          -  Males with fertility and females of childbearing age must take effective contraceptive&#xD;
             measures at least since signing informed consent until 180 days after the end of&#xD;
             concurrent radiotherapy and chemotherapy. Childbearing age means pre-menopausal or&#xD;
             within 2 years after menopause. Women of childbearing age must exclude pregnancy&#xD;
             before concurrent radiotherapy and chemotherapy&#xD;
&#xD;
          -  Patients with normal organ function prior to treatment, the following criteria are&#xD;
             met:a) blood routine examination criteria : i) hemoglobin (HB) ≥90g/L; ii) absolute&#xD;
             neutrophil count (ANC) ≥1.5×10e9/L; iii) platelet (PLT) ≥70×10e9/L; b) biochemical&#xD;
             tests meet the following criteria: i) serum creatinine (Cr) ≤1.5 times of upper limit&#xD;
             of normal (ULN) or creatinine clearance (CCr) ≥40ml/min; ii) total bilirubin (TBIL)&#xD;
             ≤1.5 ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5&#xD;
             ULN, e）Coagulation test: International Normalized Ratio (INR)≤ 1.5 × ULN, Prothrombin&#xD;
             Time ≤ 1.5 × ULN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with signet ring cell carcinoma or mucinous adenocarcinoma.&#xD;
&#xD;
          -  Patients who refuse to undergo hyperthermia or cannot cooperate with continuous&#xD;
             follow-up.&#xD;
&#xD;
          -  Patients with severe bleeding tendency, severe infection, wounds or infections on the&#xD;
             skin of the hyperthermia area.&#xD;
&#xD;
          -  Patients who have metal implants or pacemakers in their bodies who cannot tolerate&#xD;
             excessively high temperatures.&#xD;
&#xD;
          -  Other primary malignant tumors occurred within 5 years before concurrent radiotherapy&#xD;
             and chemotherapy, except for malignant tumors that have undergone radical treatment&#xD;
             and are locally curable (such as basal or squamous cell skin cancer, superficial&#xD;
             bladder cancer or prostate, cervical or breast carcinoma in situ, etc.).&#xD;
&#xD;
          -  Suffer from uncontrollable comorbid diseases, including but not limited to symptomatic&#xD;
             congestive heart failure, uncontrollable hypertension, unstable angina, arrhythmia,&#xD;
             active peptic ulcer or bleeding disease.&#xD;
&#xD;
          -  Patients with a history of alcohol or drug abuse.&#xD;
&#xD;
          -  Patients who do not agree to participate in this study or unable to complete the&#xD;
             informed consent process.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hao Wang, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hao Wang, Doctor</last_name>
    <phone>82264911</phone>
    <email>wanghaobysy@bjmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuxia Wang</last_name>
    <phone>82265968</phone>
    <email>lily31415926@126.com</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 17, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 7, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locally advanced rectal cancer</keyword>
  <keyword>hyperthermia</keyword>
  <keyword>neoadjuvant therapy</keyword>
  <keyword>chemoradiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

